{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:45:23Z","timestamp":1776728723496,"version":"3.51.2"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["PTQ-PTQ-16-08333"],"award-info":[{"award-number":["PTQ-PTQ-16-08333"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["BioExcel-3 101093290"],"award-info":[{"award-number":["BioExcel-3 101093290"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["BU067P20"],"award-info":[{"award-number":["BU067P20"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/00256"],"award-info":[{"award-number":["PI22\/00256"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI18\/00441"],"award-info":[{"award-number":["PI18\/00441"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.biopha.2024.117756","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:02:09Z","timestamp":1734393729000},"page":"117756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6028-7785","authenticated-orcid":false,"given":"Cristina","family":"Ben\u00edtez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-2107","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6178-6404","authenticated-orcid":false,"given":"Martin","family":"Kotev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-5493","authenticated-orcid":false,"given":"Marta","family":"P\u00e9rez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0462-8650","authenticated-orcid":false,"given":"Yvonne","family":"Westermaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-2571","authenticated-orcid":false,"given":"Luc\u00eda","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Korrodi-Greg\u00f3rio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-3084","authenticated-orcid":false,"given":"Pere","family":"Fontova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Aurora","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"P\u00e9rez-Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-8388","authenticated-orcid":false,"given":"Mar\u00eda","family":"Garc\u00eda-Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-7157","authenticated-orcid":false,"given":"Roberto","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Soliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-3595","authenticated-orcid":false,"given":"Vanessa","family":"Soto-Cerrato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117756_bib1","series-title":"In Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications","first-page":"229","article-title":"Use of Molecular Docking as a Decision-Making Tool in Drug Discovery","author":"Abdolmaleki","year":"2021"},{"issue":"53","key":"10.1016\/j.biopha.2024.117756_bib2","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","article-title":"Survivin, versatile modulation of cell division and apoptosis in cancer","volume":"22","author":"Altieri","year":"2003","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.biopha.2024.117756_bib3","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.233130","article-title":"A direct interaction between survivin and myosin II is required for cytokinesis","volume":"132","author":"Babkoff","year":"2019","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2012.05.030","article-title":"A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261","volume":"127","author":"Bible","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"Pt 14","key":"10.1016\/j.biopha.2024.117756_bib5","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1242\/jcs.00612","article-title":"Survivin is required for stable checkpoint activation in taxol-treated HeLa cells","volume":"116","author":"Carvalho","year":"2003","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.117756_bib6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s10637-012-9917-4","article-title":"Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells","volume":"31","author":"Castro-Gamero","year":"2013","journal-title":"Investig. N. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/app11010335","article-title":"An updated review of smac mimetics, LCL161, birinapant, and GDC-0152 in cancer treatment","volume":"11","author":"Chang","year":"2021","journal-title":"Appl. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.117756_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/jso.22134","article-title":"Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer","volume":"105","author":"Chu","year":"2012","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117756_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10637-013-9935-x","article-title":"Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)","volume":"31","author":"Erba","year":"2013","journal-title":"Investig. N. Drugs"},{"issue":"22","key":"10.1016\/j.biopha.2024.117756_bib10","first-page":"5030","article-title":"Promises and challenges of smac mimetics as cancer therapeutics","volume":"21","author":"Fulda","year":"2015","journal-title":"Clin. Cancer Res.\u00a0Off. J. Am. Assoc. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2024.117756_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevOncog.2017020836","article-title":"Yin Yang 1 (YY1): regulation of survivin and its role in invasion and metastasis","volume":"22","author":"Galloway","year":"2017","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.biopha.2024.117756_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10040879","article-title":"Prognostic significance of survivin expression in patients with ovarian carcinoma: a meta-analysis","volume":"10","author":"Gasowska-Bajger","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.117756_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/neuonc\/nor230","article-title":"Phase I study of terameprocol in patients with recurrent high-grade glioma","volume":"14","author":"Grossman","year":"2012","journal-title":"Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1158\/1078-0432.CCR-12-0647","article-title":"Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex","volume":"19","author":"Guvenc","year":"2013","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"7\u20138","key":"10.1016\/j.biopha.2024.117756_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10495-022-01734-z","article-title":"XIAP as a multifaceted molecule in cellular signaling","volume":"27","author":"Hanifeh","year":"2022","journal-title":"Apoptosis: Int. J. Program. Cell Death"},{"issue":"28","key":"10.1016\/j.biopha.2024.117756_bib17","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","article-title":"Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors","volume":"32","author":"Infante","year":"2014","journal-title":"J. Clin. Oncol.\u00a0Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117756_bib18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2007.07.045","article-title":"Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together","volume":"131","author":"Jeyaprakash","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2024.117756_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyad029","article-title":"A phase Ib dose-escalation study of LCL161 plus oral topotecan for patients with relapsed\/refractory small cell lung cancer and select gynecologic malignancies","volume":"28","author":"Johnson","year":"2023","journal-title":"Oncologist"},{"issue":"6001","key":"10.1016\/j.biopha.2024.117756_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.1189505","article-title":"Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B","volume":"330","author":"Kelly","year":"2010","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2007.08.074","article-title":"Phase I\/II clinical safety studies of terameprocol vaginal ointment","volume":"107","author":"Khanna","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117756_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cam4.363","article-title":"A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma","volume":"4","author":"Kudchadkar","year":"2015","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.biopha.2024.117756_bib24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-dependent exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2024.117756_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-10-168","article-title":"Fpocket: an open source platform for ligand pocket detection","volume":"10","author":"Le Guilloux","year":"2009","journal-title":"BMC Bioinforma."},{"issue":"12","key":"10.1016\/j.biopha.2024.117756_bib26","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/emboj\/cdg307","article-title":"Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension","volume":"22","author":"Lens","year":"2003","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib27","first-page":"270","article-title":"Effects of survivin on angiogenesis in vivo and in vitro","volume":"8","author":"Li","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib28","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3892\/ol.2017.6626","article-title":"Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer","volume":"14","author":"Li","year":"2017","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.biopha.2024.117756_bib29","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.jid.5700381","article-title":"Activation of dual apoptotic pathways in human melanocytes and protection by survivin","volume":"126","author":"Liu","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117756_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.prp.2019.01.025","article-title":"Survivin as a diagnostic and therapeutic marker for thyroid cancer","volume":"215","author":"Mahmoudian-Sani","year":"2019","journal-title":"Pathol.\u00a0Res. Pract."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00345-007-0219-y","article-title":"Survivin: a promising biomarker for detection and prognosis of bladder cancer","volume":"26","author":"Margulis","year":"2008","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/med.21547","article-title":"Therapeutic strategies involving survivin inhibition in cancer","volume":"39","author":"Mart\u00ednez-Garc\u00eda","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2024.117756_bib33","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/emboj\/cdg263","article-title":"HBXIP functions as a cofactor of survivin in apoptosis suppression","volume":"22","author":"Marusawa","year":"2003","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2013.11.013","article-title":"YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression","volume":"132","author":"Mir","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"0","key":"10.1016\/j.biopha.2024.117756_bib35","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117756_bib36","first-page":"e427","article-title":"A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors. Asia-Pacific","volume":"18","author":"Morita","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.117756_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211035269","article-title":"Asenapine: an atypical antipsychotic with atypical formulations","volume":"11","author":"Musselman","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117756_bib38","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1091\/mbc.e11-11-0904","article-title":"A highlights from MBoC selection: molecular basis for phosphospecific recognition of histone H3 tails by survivin paralogues at inner centromeres","volume":"23","author":"Niedzialkowska","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.biopha.2024.117756_bib39","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3109\/10428194.2015.1113275","article-title":"A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma","volume":"57","author":"Papadopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"26","key":"10.1016\/j.biopha.2024.117756_bib40","doi-asserted-by":"crossref","first-page":"23296","DOI":"10.1074\/jbc.M111.237586","article-title":"Survivin monomer plays an essential role in apoptosis regulation","volume":"286","author":"Pavlyukov","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.117756_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116761","article-title":"A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells","volume":"65","author":"Peery","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/0008-5472.CAN-15-1874","article-title":"Effective targeting of the survivin dimerization interface with small-molecule inhibitors","volume":"76","author":"Qi","year":"2016","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2024.117756_bib43","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"issue":"22","key":"10.1016\/j.biopha.2024.117756_bib44","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.2174\/092986712801661040","article-title":"Survivin as a prognostic\/predictive marker and molecular target in cancer therapy","volume":"19","author":"Rodel","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib45","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1091\/mbc.e05-08-0723","article-title":"Survivin modulates microtubule dynamics and nucleation throughout the cell cycle","volume":"17","author":"Rosa","year":"2006","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.biopha.2024.117756_bib46","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1158\/2767-9764.CRC-24-0102","article-title":"Clinical efficacy of the HIV protease inhibitor indinavir in combination with chemotherapy for advanced classic kaposi sarcoma treatment: a single-arm, phase ii trial in the elderly","volume":"4","author":"Sgadari","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117756_bib48","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s00204-018-2240-x","article-title":"Sensitization of colorectal cancer cells to irinotecan by the Survivin inhibitor LLP3 depends on XAF1 proficiency in the context of mutated p53","volume":"92","author":"Steigerwald","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2024.117756_bib49","unstructured":"Sycrest European Medicines Agency. (n.d.). Retrieved September 19, 2023, from \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sycrest\u3009."},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib50","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10637-014-0198-y","article-title":"Phase I study of the novel Cdc2\/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias","volume":"33","author":"Tibes","year":"2015","journal-title":"Investig. N. Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2024.117756_bib51","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"issue":"11","key":"10.1016\/j.biopha.2024.117756_bib52","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.bmcl.2007.03.042","article-title":"Discovery of a novel small molecule binding site of human survivin","volume":"17","author":"Wendt","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.biopha.2024.117756_bib53","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.biopha.2024.117756_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2013.10.039","article-title":"A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel\/prednisone in patients with castration-resistant prostate cancer","volume":"65","author":"Wiechno","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2024.117756_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib56","article-title":"BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration","volume":"11","author":"Xu","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117756_bib57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2015.3947","article-title":"Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma","volume":"34","author":"Yu","year":"2015","journal-title":"Oncol. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224016421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:14:47Z","timestamp":1776726887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224016421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S0753332224016421"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117756","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117756"}}